114 results about "Ocular implant" patented technology

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include at least two implants preloaded within a delivery device and configured to be implanted within the eye, a metering device configured to transfer energy to the implants for delivery at selected locations within the eye, wherein the metering device is configured to meter a variable amount of energy for each implant delivery event in the eye. The system can further include an injector mechanism configured to serially engage and drive each of the implants.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include at least two implants preloaded within a delivery device and configured to be implanted within the eye, a metering device configured to transfer energy to the implants for delivery at selected locations within the eye, wherein the metering device is configured to meter a variable amount of energy for each implant delivery event in the eye. The system can further include an injector mechanism configured to serially engage and drive each of the implants.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Systems and methods for delivering an implant to treat an ocular disorder is disclosed. The ocular implant can include a treatment fluid that is released over the course of several days or months to treat an ocular disorder. A system for implanting and retrieving spent implants can include an implant, an external housing, and an implant assembly. The external housing can provide access to a sliding trigger. The sliding trigger can convert a portion of the implant assembly from a first configuration to a second configuration and a second configuration to a third configuration to release or retrieve an implant. In some embodiments, the implant assembly can include a collet formed from sheet metal and bent to act as a spring. The collet can have protrusions to match the profile of an implant to secure the implant during delivery. Actuation of the trigger can relieve the spring's pressure.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include a plurality of implants, an external housing, and an introducer assembly. The external housing can provide access to an implant singulation actuator and an implant delivery actuator. The introducer assembly can comprise an auto-retracting introducer portion. The delivery apparatus can include an infinite activation mechanism / portion and / or a manual singulation mechanism / portion.

Disclosed herein are systems, devices, kits, and associated methods for treating conditions of the eye by reducing intraocular pressure. The system may include an ocular implant and a delivery device. The ocular implant may be implantable within Schlemm's canal to restore or maintain at least partial patency of the canal without substantially interfering with transmural or transluminal fluid flow across the canal. The delivery device may include a cannula comprising a straight proximal portion and a curved distal portion, where the curved distal portion comprises a first curve in a first direction. The delivery device may also include a positioning tool positioned at least partially within the cannula and configured to advance the ocular implant through the cannula, where the positioning tool comprises a curved distal portion biased to form a second curve in a second, different direction.

A medical device for office-based / operating room bleb forming minimally invasive glaucoma surgeries. The medical device includes a proximal segment for grasping by a user, a distal segment that includes a piercing member coupled to and extending from the distal segment, wherein the piercing member is configured to contain and deliver an ocular implant into an eye tissue layer to obtain a channel, wherein the proximal segment and the distal segment being configured to couple to each other at a pivot point between an unlocked configuration and a locked configuration, and wherein in the unlocked configuration, the proximal segment and the distal segment are rotatable relative to each other about a rotation axis at the pivot point.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include a plurality of implants, an external housing, and an introducer assembly. The external housing can provide access to an implant singulation actuator and an implant delivery actuator. The introducer assembly can comprise an auto- retracting introducer portion. The delivery apparatus can include an infinite activation mechanism / portion and / or a manual singulation mechanism / portion.

Described herein are insertion devices configured to achieve an efficient delivery and placement of a thin-film implant into a surgical site that is open or minimally invasive. An example insertion device includes a distal portion configured to enclose and protect a thin-film implant device during delivery and placement into a surgical site, wherein the distal portion includes a top half and a bottom half, and the thin-film implant device is placed between the top half and the bottom half; a support structure positioned between the top half and the bottom half and adjacent a proximal end of the thin-film implant device, wherein the top and bottom halves are retractable independently of one another.

The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The present application discloses an ocular implant delivery device including: a housing, a rotating wheel, a push needle linkage assembly, a retracting linkage assembly, a sleeve, and a puncture needle. The housing is provided with a through hole at a distal end of the housing, and the sleeve extends an inside of the housing to an outside of the housing through the through hole, and is connected to the housing. The puncture needle runs through the sleeve, a proximal end of the puncture needle is fixedly connected to the retracting linkage assembly, and a push needle of the push needle linkage assembly runs through an inner hole of the puncture needle. The rotating wheel is connected to an inside of the housing via rotating shafts, an opening corresponding to the rotating wheel is provided on the housing.

This invention discloses an ocular implant and its delivery system, comprising: a flexible substrate; multiple nanowire arrays disposed on the flexible substrate; an elastic ring disposed along the circumferential edge of the flexible substrate, the elastic ring having elastic memory and capable of returning to its original shape before deformation after deformation; and two opposing openings disposed near the edge of the flexible substrate. The nanowire array of the ocular implant of this invention can be composed of multiple materials spliced ​​together, and materials with different efficacies and photosensitive wavelengths can be selected for splicing. Therefore, personalized ocular implants can be customized according to different patient conditions to achieve a better match with the patient's fundus condition. Furthermore, the folding and opening design of the ocular implant of this invention, as well as the self-expanding property of the elastic ring, enable it to be adapted to a delivery system for positioning and minimally invasive implantation.

DRUG ELUTING OCULAR IMPLANT

The invention relates to a sustained release biodegradable ocular implant containing axitinib dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

A fenestration template device includes a main body extending along a longitudinal axis between a first end and a second end of the device. The device includes an outer surface extending from the first surface to the second surface. The device includes a central lumen defined by the main body along the longitudinal axis, the central lumen extending from a first opening at the first surface to a second opening at the second surface. The device includes a plurality of side lumens defined by a plurality of side openings in the outer surface and extending from the side openings, through the main body, and into the central lumen. The device is configured for accepting a tube of an ocular implant (e.g., a glaucoma drainage implant) in the central lumen. The device is further configured for accepting a needle or suturing device in the plurality of side lumens.

An insertion device for an ocular implant for regulating intraocular pressure includes a cannula having an internal space for receiving at least a portion of an ocular implant having a stent and an implant opening for inserting the ocular implant; a handle configured to be connected to the cannula and held by a surgeon; and a holder configured to be coupled to the handle and including a receiving portion configured to receive the stent of the ocular implant. The ocular implant insertion device appropriately fixes the stent inserted into the tube of the ocular implant in a manner attached to the insertion device, thereby preventing problems such as the stent coming out of the tube, the implant being separated from the insertion device by the stent, or the stent obscuring the surgeon's field of vision during implant implantation surgery.

Disclosed is an ocular implant with a flexible leading tip and methods of deploying the ocular implant. The leading tip can comprise a tip distal segment and a tip proximal segment. The leading tip can be tapered such that a diameter or width of the leading tip along the tip proximal segment is greater than the diameter or width of the leading tip along the tip distal segment.

An ocular implant adapted to be disposed within Schlemm's canal of a human eye with a body extending along a curved longitudinal central axis in a curvature plane, a first strut on one side of the implant and a second strut on an opposite side of the implant, the circumferential extent of the first strut with respect to the plane of curvature being greater than the circumferential extent of the second strut with respect to the plane of curvature. The invention also includes methods of using the implant.

The present disclosure relates to methods of preparing biodegradable ocular implants containing edonentan, or a pharmaceutically acceptable salt thereof. The disclosure also relates to biodegradable ocular implants generally comprising a biodegradable polymer and edonentan, or a pharmaceutically acceptable salt thereof.

The present application discloses an ocular implant delivery device comprising a housing, a rotating wheel, a push needle linkage assembly, a retracting linkage assembly, a sleeve, and a puncture needle. A through hole is provided at a distal end of the housing, and the sleeve extends from an inside of the housing to an outside of the housing through hole and is fixedly connected to the housing. The puncture needle runs through the sleeve, and an end of the puncture needle facing away from a needle tip of the puncture needle is fixedly connected to the retracting linkage assembly. A push needle of the push needle linkage assembly extends through an inner hole of the puncture needle, the rotating wheel is connected to the housing via a rotating shaft, and an opening corresponding to the rotating wheel is provided on the housing.

The invention relates to an extra-ocular implant (1) used to prevent worsening of pathological myopia, the implant comprising a support structure (10) produced in the form of an arm having, at a first end, anchoring means and a second end comprising a concavity (120), the implant (1) being characterized in that it further comprises a pouch (13) in which a compound suitable for inflating the pouch (13) is arranged, the pouch (13) being positioned at the second end of the arm so as to occupy the concavity (120), the implant (1) further comprising an attachment device (130) arranged on the pouch (13) for positioning against the posterior portion of the eye.

A medical device for office-based / operating room bleb forming minimally invasive glaucoma surgeries. The medical device includes a proximal segment for grasping by a user, a distal segment that includes a piercing member coupled to and extending from the distal segment, wherein the piercing member is configured to contain and deliver an ocular implant into an eye tissue layer to obtain a channel, wherein the proximal segment and the distal segment being configured to couple to each other at a pivot point between an unlocked configuration and a locked configuration, and wherein in the unlocked configuration, the proximal segment and the distal segment are rotatable relative to each other about a rotation axis at the pivot point.